Brazil signs letter of intent to purchase five COVID vaccines
Reuters
Published Nov 22, 2020 05:26PM ET
BRASILIA (Reuters) - Brazil's health ministry said on Sunday it will sign non-binding letters of intent to purchase coronavirus vaccines from four companies and Russia's sovereign wealth fund, adding that any purchase will depend on the approval of the nation's regulators.
According to the ministry, officials met last week with representatives of Pfizer Inc (NYSE:PFE), India's Bharat Biotech, the Russian Direct Investment Fund, Moderna (NASDAQ:MRNA) Inc and Janssen, a unit of Johnson & Johnson (NYSE:JNJ).
In a statement, the ministry said its legal and technical departments were analyzing the documents presented by the five entities and determining the best way to go about purchasing vaccines at "the opportune moment."
The government has contracts in place to guarantee access to 142,900,000 coronavirus vaccine doses, enough to immunize at least a third of Brazil's population, officials said in the statement.
So far, the Brazilian federal government's main bet is on a vaccine being developed by AstraZeneca (NASDAQ:AZN) PLC, with which it has already signed a supply contract.
In Sao Paulo, Brazil's largest state, local authorities have signed a deal with China's Sinovac Biotech Ltd to test and produce a vaccine locally. Brazilian President Jair Bolsonaro, a long-time critic of China, has dismissed that vaccine as untrustworthy, without presenting evidence.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.